Abstract:Sir, Penile squamous cell carcinoma (SCC) is a rare malignancy.[1] Neoadjuvant chemotherapy represents the standard of treatment for patients with locally advanced penile SCC.[2] Recently, our previous study noted that the overexpression of epidermal growth factor receptor (EGFR) was common and mutations of KRAS and BRAF were rare in penile SCC, which suggested anti-EGFR antibody might be potentially beneficial to penile SCC.[3] Here, we describe a patient with locally advanced penile SCC using neoadjuvant chemotherapy with cetuximab (an anti-EGFR antibody). In November 2013, a 68-year-old man, complaining about masses in his penis and groin, was diagnosed as penile SCC by pathological examination after fine-needle aspiration. Then, the patient received the total penectomy in the local hospital. However, the masses in his groin grew rapidly with secondary bacterial infection [Figure 1a]. He was referred to our hospital for further treatment in December 2013. Computed tomography showed enlarged soft tissue shadows in his bilateral inguinal region [Figure 2a and b]. KRAS and BRAF gene status analysis of the tumor showed wild types. Obviously, the tumor was considered unresectable. Then the patient started neoadjuvant therapy with cetuximab 800 mg on day 1 plus chemotherapy with paclitaxel 210 mg on day 1 and cisplatin 30 mg on day 1-3 every 2 weeks, and anti-infection treatment was also performed. After two chemotherapeutic cycles, his tumor achieved a partial response (PR) with a significant reduction in masses size and complete control of the infection [Figure 2c and d]. After completion of the fourth course of chemotherapy, the swollen lymph nodes shrinked obviously [Figure 1b]. Then he successfully underwent bilateral inguinal lymph node dissection in April 2014. Histopathological examination revealed that cancerous metastases were found in six lymph nodes. After 2 months recurrence-free time, unfortunately, the patient suffered a tumor recurrence in his right groin.Figure 1: (a) Pink cutaneous nodular lesions in the groin were red and swollen before cetuximab and chemotherapy. (b) The swollen nodular lesion regression was obvious after cetuximab and chemotherapyFigure 2: Computed tomography showing enlarged tissue shadows in the right (a) and left (b) groin region before cetuximab and chemotherapy. Two cycles later, partial response was achieved with a significant reduction in masses size (c and d)Although long disease-free time was not achieved in this case, a PR was achieved and bilateral inguinal lymph node dissection was completed. The good clinical response to cetuximab-containing chemotherapy followed by successful radical surgery suggested potential application of cetuximab in neoadjuvant therapy for locally advanced penile SCC. As we know, cisplatin-containing chemotherapy is now considered the first choice in neoadjuvant setting for advanced penile cancer; however, the prognosis of advanced penile SCC is poor.[24] The chemotherapy regimen of three-drug combination likely leads to greater response, but more adverse reactions. In the prospective trial of neoadjuvant chemotherapy for advanced penile SCC (paclitaxel, cisplatin, and ifosfamide), a number of grades 3 and 4 adverse events were occurred.[2] Theoretically, replacing a kind of chemotherapy drug with cetuximab may reduce the overlap of possible adverse effects among chemotherapy drugs. In this case, mild acne-like rashes were observed due to cetuximab-related toxicity and the regimen was well-tolerated. Given the rarity of the disease, the realization of a prospective trial will be difficult. The experience of treatment for penile SCC should be gathered case by case. Future investigations of anti-EGFR antibody in neoadjuvant setting for locally advanced penile SCC are warranted.

Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma.

Anti-EGFR Antibody Plus Anti-Pd-1 Antibody and Chemotherapy As a Neoadjuvant Regimen for Patients with Locally-Advanced Penile Squamous Cell Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial.

Camrelizumab combined with TIP (paclitaxel+cisplatin+ifosfamide) as neoadjuvant treatment of locally advanced penile cancer before lymphadenectomy: An exploratory, phase II study.

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

[Efficacy and Safety of Neoadjuvant Toripalimab Combined with Nimotuzumab and Chemotherapy in Patients with Unresectable Stage Ⅳ Squamous Cell Carcinoma of Penis].

Neoadjuvant Docetaxel, Cisplatin and Ifosfamide (ITP) Combination Chemotherapy for Treating Penile Squamous Cell Carcinoma Patients with Terminal Lymph Node Metastasis

EGFR Mono-Antibody Salvage Therapy for Locally Advanced and Distant Metastatic Penile Cancer: Clinical Outcomes and Genetic Analysis.

Neoadjuvant Pd-1 Inhibitor (Toripalimab) Plus Chemotherapy In Patients With Potentially Resectable Nsclc: An Open-Label, Single-Arm, Phase Ii Trial

First-line Programmed Death Receptor-1 (PD-1) Inhibitor and Epidermal Growth Factor Receptor (EGFR) Blockade, Combined with Platinum-Based Chemotherapy, for Stage IV Penile Cancer.

First‐line PD‐1 Inhibitor & EGFR Blockade & Platinum‐based Chemotherapy (PEP) for Stage IV Penile Cancer

Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer

Neoadjuvant Chemoradiotherapy Combined with Perioperative Toripalimab in Locally Advanced Esophageal Cancer.

Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.

415 Toripalimab Plus Nab-Paclitaxel and Carboplatin As Neoadjuvant Therapy for Patients with Esophageal Squamous Cell Carcinoma at Clinical Stage T2-T4/N0-N2/M0: a Single-Arm, Single-Center Clinical Study

Toripalimab Combined with Docetaxel and Cisplatin Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Single-Center, Single-Arm Clinical Trial (ESONICT-2).

Neoadjuvant trial with toripalimab, albumin paclitaxel, and cisplatin on pathological response in locally advanced resectable oral squamous cell carcinoma (Illuminate Trial).

Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.

Neoadjuvant Chemotherapy with Cetuximab for Locally Advanced Penile Cancer

Toripalimab Plus Paclitaxel And Carboplatin As Neoadjuvant Therapy In Patients With Locally Advanced Resectable Esophageal Squamous Carcinoma: An Open-Label, Single Arm Phase 2 Trial.

A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.

Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations: A Multi-Center, Multi-Cohort, Exploratory Study.